GLP-1 receptor agonists work by: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppressing glucagon release when blood glucose levels are elevated Slowing gastric emptying, which moderates post-meal glucose rises (this effect may attenuate over time) Reducing appetite through effects on brain centres controlling satiety Understanding this pharmacological profile is essential when considering the hypoglycaemic potential of Wegovy
[4] SUSTAIN-6 (semaglutide) : In 3,297 high-risk patients with type 2 diabetes, once-weekly semaglutide reduced major cardiovascular events by 26% and stroke by 39% over two years
E.KurzawinskiT
General Information The incretin concept arose with the realization that oral glucose induced a greater increase in insulin secretion than did intravenous administration in normal humans (71)
17: 5660 Brass EP, Hoppel CL, Hiatt WR
Both retatrutide pens are subcutaneous, multi-dose devices delivering the triple GIP/GLP-1/glucagon receptor agonist in adjustable increments, matching the titration schedule used across the Jastreboff Phase 2 cohort and the ongoing TRIUMPH Phase 3 programme [1] [unverified]
